Fresenius Medical Care AG & Co. KGaA (FMS) Stock

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Fresenius Medical Care AG & Co. KGaA is headquartered in DE.

Fresenius Medical Care AG & Co. KGaA (FMS) stock trades at $23.69 with a market capitalization of $12.72B. The stock is valued at a price-to-earnings (P/E) ratio of 12.64, price-to-book of 0.86, price-to-sales of 0.58. Over the past 52 weeks the stock has ranged between $20.02 and $27.64, and currently trades 14.3% below its 52-week high. It pays a dividend yielding 3.63%.

On profitability, Fresenius Medical Care AG & Co. KGaA generates a return on equity (ROE) of 7.16%, return on capital employed of 7.96%, an operating margin of 10.17%, a net profit margin of 4.88%.

Official website: www.freseniusmedicalcare.com

Fresenius Medical Care AG & Co. KGaA by the numbers, 2016–2025

Between 2016 and 2025 Fresenius Medical Care AG & Co. KGaA reported revenue of $17.0B rising to $19.6B, a change of +15.3% across 10 years. Compounded, revenue has grown 1.9% a year over five years, 0.4% over three, 1.5% over the last twelve months. Net profit fell to $978.0M.

Operating margin went from 14.7% in 2016 to 9.3% in 2025, a fall of 5.4 percentage points. The most recent net margin is 4.88%. On a trailing twelve-month basis to Mar '26, revenue is $19.4B and net profit $945.0M.

Borrowings rose from $8.1B to $10.8B, cash on hand is $1.6B, cash from operations was $2.6B in the latest year, positive in 10 of the last 10.

Return on equity has averaged 5.3% over five years, and was 6.8% in the most recent year.

The share price itself has compounded at -7.8% a year over five years, -0.2% over three, -8.4% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Fresenius Medical Care AG & Co. KGaA (FMS) — frequently asked questions